BACKGROUND: The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immunodeficiency virus type 1 (HIV-1) entry into T-cells and a variant allele, CCR5 delta-32, is associated with decreased viral replication and disease progression. Active HIV-1 replication is highly associated with accelerated rates of hepatic fibrosis. We postulated that CCR5 plays a role in the development of hepatic fibrosis and evaluated the longitudinal effect of natural or drug-induced CCR5 mutation and blockade on biomarkers of liver fibrosis in HIV-1 patients. METHODS: To accomplish this goal, we examined 2 distinct cohorts. First, we evaluated fibrosis markers in the Multicenter Hemophilia Cohort Studies (MHCS), which included subjects with HIV and hepatitis C virus (HCV) coinfection with the CCR5 delta-32 allele. We also evaluated an HIV-1 infected cohort that was treated with a dual CCR5/CCR2 antagonist, cenicriviroc. The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCV patients and demonstrated strong correlation with fibrosis stage. RESULTS: In both the MHCS patients and patients treated with cenicriviroc, CCR5 mutation or blockade was associated with a significant decrease in the ELF index. Among the patients with the delta-32 allele, the ELF index rate significantly decreased in sequential samples as compared to CCR5 wild-type patients (P = .043). This was not observed in control subjects treated with efavirenz nor with a lower dose of 100 mg cenicriviroc. CONCLUSION: These findings suggest that hepatic fibrosis in HIV-1 infected patients can be modulated by the mutation of CCR5 and/or use of CCR5/CCR2 blockade agents. CLINICAL TRIALS REGISTRATION: NCT01338883.
BACKGROUND: The C-C chemokine receptor Type 5 (CCR5) is a key receptor for human immunodeficiency virus type 1 (HIV-1) entry into T-cells and a variant allele, CCR5 delta-32, is associated with decreased viral replication and disease progression. Active HIV-1 replication is highly associated with accelerated rates of hepatic fibrosis. We postulated that CCR5 plays a role in the development of hepatic fibrosis and evaluated the longitudinal effect of natural or drug-induced CCR5 mutation and blockade on biomarkers of liver fibrosis in HIV-1patients. METHODS: To accomplish this goal, we examined 2 distinct cohorts. First, we evaluated fibrosis markers in the Multicenter Hemophilia Cohort Studies (MHCS), which included subjects with HIV and hepatitis C virus (HCV) coinfection with the CCR5 delta-32 allele. We also evaluated an HIV-1 infected cohort that was treated with a dual CCR5/CCR2 antagonist, cenicriviroc. The enhanced liver fibrosis (ELF) index was validated against liver histology obtained from HCV/HIV and HCVpatients and demonstrated strong correlation with fibrosis stage. RESULTS: In both the MHCS patients and patients treated with cenicriviroc, CCR5 mutation or blockade was associated with a significant decrease in the ELF index. Among the patients with the delta-32 allele, the ELF index rate significantly decreased in sequential samples as compared to CCR5 wild-type patients (P = .043). This was not observed in control subjects treated with efavirenz nor with a lower dose of 100 mg cenicriviroc. CONCLUSION: These findings suggest that hepatic fibrosis in HIV-1 infectedpatients can be modulated by the mutation of CCR5 and/or use of CCR5/CCR2 blockade agents. CLINICAL TRIALS REGISTRATION: NCT01338883.
Authors: Yan Liu; Heng Liu; Christoph Meyer; Jun Li; Silvio Nadalin; Alfred Königsrainer; Honglei Weng; Steven Dooley; Peter ten Dijke Journal: J Biol Chem Date: 2013-09-04 Impact factor: 5.157
Authors: Jana C Mossanen; Oliver Krenkel; Can Ergen; Olivier Govaere; Anke Liepelt; Tobias Puengel; Felix Heymann; Sandra Kalthoff; Eric Lefebvre; Dirk Eulberg; Tom Luedde; Gernot Marx; Christian P Strassburg; Tania Roskams; Christian Trautwein; Frank Tacke Journal: Hepatology Date: 2016-07-22 Impact factor: 17.425
Authors: Shadi Salloum; Jacinta A Holmes; Rohit Jindal; Shyam S Bale; Cynthia Brisac; Nadia Alatrakchi; Anna Lidofsky; Annie J Kruger; Dahlene N Fusco; Jay Luther; Esperance A Schaefer; Wenyu Lin; Martin L Yarmush; Raymond T Chung Journal: Hepatology Date: 2016-10-05 Impact factor: 17.425
Authors: Mark A Wallet; Carina A Rodriguez; Li Yin; Sara Saporta; Sasawan Chinratanapisit; Wei Hou; John W Sleasman; Maureen M Goodenow Journal: AIDS Date: 2010-06-01 Impact factor: 4.177
Authors: Marion G Peters; Peter Bacchetti; Ross Boylan; Audrey L French; Phyllis C Tien; Michael W Plankey; Marshall J Glesby; Michael Augenbraun; Elizabeth T Golub; Roksana Karim; Julie Parkes; William Rosenberg Journal: AIDS Date: 2016-03-13 Impact factor: 4.177
Authors: Jason M Brenchley; David A Price; Timothy W Schacker; Tedi E Asher; Guido Silvestri; Srinivas Rao; Zachary Kazzaz; Ethan Bornstein; Olivier Lambotte; Daniel Altmann; Bruce R Blazar; Benigno Rodriguez; Leia Teixeira-Johnson; Alan Landay; Jeffrey N Martin; Frederick M Hecht; Louis J Picker; Michael M Lederman; Steven G Deeks; Daniel C Douek Journal: Nat Med Date: 2006-11-19 Impact factor: 53.440
Authors: Eric Lefebvre; Graeme Moyle; Ran Reshef; Lee P Richman; Melanie Thompson; Feng Hong; Hsin-L Chou; Taishi Hashiguchi; Craig Plato; Dominic Poulin; Toni Richards; Hiroyuki Yoneyama; Helen Jenkins; Grushenka Wolfgang; Scott L Friedman Journal: PLoS One Date: 2016-06-27 Impact factor: 3.240
Authors: Jason T Blackard; Ling Kong; Susan D Rouster; Rebekah Karns; Paul S Horn; Shyam Kottilil; M Tarek Shata; Kenneth E Sherman Journal: PLoS One Date: 2019-10-29 Impact factor: 3.240
Authors: Dana Gabuzda; Beth D Jamieson; Ronald G Collman; Michael M Lederman; Tricia H Burdo; Steven G Deeks; Dirk P Dittmer; Howard S Fox; Nicholas T Funderburg; Savita G Pahwa; Ivona Pandrea; Cara C Wilson; Peter W Hunt Journal: Pathog Immun Date: 2020-06-17